Rosiglitazone

Drugs

Volumn 57, Issue 6, 1999, Pages 921-930

  Barman Balfour, Julia A ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CYTOCHROME P450; DIGOXIN; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; RANITIDINE; ROSIGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; TROGLITAZONE;

ANEMIA; AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG ELIMINATION; DRUG HALF LIFE; EDEMA; GLUCOSE BLOOD LEVEL; HEADACHE; HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS DISEASE; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; POLYPHARMACY; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0033044593     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957060-00007     Document Type: Review

References (66)

1. 1. Whitcomb RW, Saltiel AR. Thiazolidinediones. Expert Opin Invest Drug 1995; 4 (12): 1299-309
2. 2. Henry RR. Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am J Med 1998 Jul 6; 105 Suppl. 1A: 20S-6S
3. 3. Bloomgarden ZT. Insulin resistance: current concepts. Clin Ther 1998 Mar-Apr: 20: 216-31
4. 4. Grossman SL, Lessem J. Mechanisms and clinical effects of thiazolidinediones. Expert Opin Invest Drug 1997; 6 (8): 1025-40
5. 5. Oakes ND, Kennedy CJ, Jenkins AB, et al. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994 Oct; 43: 1203-10
6. 6. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 1995; 270 (22): 12953-6
7. 7. Berger J, Bailey P, Biswas C, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-τ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996 Oct; 137: 4189-95
8. 8. Spiegelman BM. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47 (4): 507-14
9. 9. Young PW, Buckle DR, Cantello BCC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J Pharmacol Exp Ther 1998 Feb; 284: 751-9
10. 10. Prins J, Adams M, Holder J, et al. Thiazolidinediones promote human pre-adipocyte differentiation and activate hPPAR γ [abstract]. J Endocrinol 1996 Mar; 148 Suppl.: P53
11. 11. De-Vos P, Lefebvre A-M, Miller SG, et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ. J Clin Invest 1996 Aug 15; 98: 1004-9
12. 12. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A 1996 Jun 11; 93: 5793-6
13. 13. Pearson SL, Cawthorne MA, Clapham JC, et al. The thiazolidinedione insulin sensitiser, BRL49653, increases the expression of PPAR-γ and aPd2 in adipose tissue of high-fat-fed rats. Biochem Biophys Res Commun 1996 Dec 24; 229: 752-7
14. 14. Pickavance L, Tadayyon M, Widdowson P. Therapeutic index for rosiglitazone in dietary obese rats and effects on body weight and plasma leptin [abstract]. Diabetic Med 1998; 15 Suppl. 2: S28
15. 15. Lefebvre A-M, Peinado-Onsurbe J, Leitersdorf I, et al. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 1997 Sep; 17: 1756-64
16. 16. Digby JE, Montague CT, Sewter CP, et al. Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 1998 Jan; 47: 138-41
17. 17. Teruel T, Smith S, Clapham J, Rosiglitazone and Wy 14643 act synergistically to enhance UCP-3 expression in brown adipocytes. Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
18. 18. Teruel T, Smith S. Differential regulation of UCP-1 expression by rosiglitazone and Wy 14643 in brown adipocytes [abstract]. Diabetes 1998 May; 47 Suppl. 1: A17
19. 19. Aubert J, Champigny O, Saint-Marc P, et al. Up-regulation of UCP-2 gene expression hy PPAR agonists in preadipose and adipose cells. Biochem Biophys Res Commun 1997 Sep 18; 238: 606-11
20. 20. Young PW, Cawthorne MA, Coyle PJ, et al. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes; association with increased insulin binding and cell-surface GLUT4 as measured hy photoaffinity labeling. Diabetes 1995 Sep; 44: 1087-92
21. 21. Lohray BB, Bhushan V, Rao BP, et al. Novel euglycemie and hypolipidemic agents: I. J Med Chem 1998 May 7; 41: 1619-30
22. 22. Lister CA, Boam D, Bretherton-Watt D, et al. Rosiglitazone increases pancreatic islet area, number and insulin content, but not insulin gene expression [abstract]. Diabetologia 1998 Aug; 41 Suppl. 1: A169
23. 23. Draper N, Clarke K, Buckingham R, et al. Rosiglitazone restores basal glucose uptake in the obese Zucker rat heart. Abstract accepted for American Diabetic Association Meeting; 1999 Jun 19-22, San Diego
24. 24. Walker A, Chattington P, Buckingham R, et al. BRL 49653, a new insulin-sensitizing agent, protects against impairment of endothelial function in Zucker fatty rats [abstract]. Diabetes 1996 May; 45 Suppl. 2: 222A
25. 25. Buckingham RE, Al-Barazanji KA, Toseland CDN, et al. Peroxisome proliferator-activated receptor-τ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998 Aug; 47: 1326-34
26. 26. Finegood DT, McArthur MU, Dunichand-Hoedl A, et al. The PPAR γ agonist, rosiglitazone, reverses hyperinsulinemia and promotes growth of islet beta-cell mass [abstract]. Diabetes 1998 May; 47 Suppl. 1: 47
27. 27. Oliver Jr W, Boneek V, Wiard R, et al. Responders and non-responders: treatment with the thiazolidinedione insulin sensitizer, BRL 49653, improves diabetic dyslipidemia more than reducing hyperglycernia in ZDF rats [abstract]. Diabetes 1996 May; 45 Suppl. 2: 316A
28. 28. Oakes ND, Camilleri S, Furier SM, et al. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat. Metabolism 1997 Aug; 46: 935-42
29. 29. Wang Q, Dryden S, Frankish HM, et al. Increased feeding in fatty Zucker rats by the thiazolidinedione BRI. 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br J Pharmacol 1997 Dec; 122: 1405-10
30. 30. Tai TAC, Jennermann C, Brown KK, et al. Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocyte differentiation. J Biol Chem 1996 Nov 22; 271: 29909-14
31. 31. Smith SA, Lister CA, Hughes MG, et al. The PPAR-γ agonist, BRI. 49653, prevents progression to diabetes in Zucker diabetic fatty rats [abstract]. Diabetologia 1997 Jun; 40 Suppl. 1: A46
32. 32. Eldershaw TPD, Rattigan S, Cawthome MA, et al. Prior treatment of obese Zucker rats with the thiazolidinedione (BRL 49653) decreases insulin resistance in perfused hindlimb [abstract]. Diabetes Care 1995 Jun; 18 Suppl 2: A16
33. 33. Smith S, Boam D, Cawthorne MA, et al. Rosiglitazone improves ínsulin sensitivity and reduces hyperexpression of insulin and amylin mRNA's in pancreatic islets [abstract]. Diabetes 1998 May; 47 Suppl. 1: A94
34. 34. Freed MI, Jorkasky DK, DiCicco RA. The bioavailability of rosiglitazone is unaltered by food. Eur J Clin Pharmacol. In press
35. 35. DiCicco R, Freed M. Allen A, et al. A study of the effect of age on the pharmacokinetics of BRL 49653C in healthy volunteers [abstract]. J Clin Pharmacol 1995 Sep; 35: 926
36. 36. Chapelsky MC, Thompson K, Miller A. Effect of renal impairment on the pharmacokinetics of rosiglitazone (RSG). Clin Pharmacol Ther 1999; 65 (2): 185
37. 37. Thompson K, Zussman B, Miller A, Pharmacokinetics of rosiglitazone are unaltered in hemodialysis patients [abstract]. Clin Pharmacol Ther 1999 Feb; 65 (2): 186
38. 38. Miller AK, Inglis AL, Thompson K. Effect of hepatic impairment on the pharmacokinetics (PK) of rosiglitazone (RSG) [abstract]. Clin Pharmacol Ther 1999 Feb: 186
39. 39. Plosker GL, Faulds D. Troglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 1999; 57 (3): 409-38
40. 40. Freed MI, Miller A, Inglis AM, et al. Rosiglitazone, a PPAR-γ agonist, does not alter the pharmacokinetics of nifedipine, a cytochrome P450 3A4-substrate [abstract]. Diabetes 1998 May; 47 Suppl. 1: A94
41. 41. Inglis AM, Miller AK, Culkin KT, et al. Rosiglitazone, a PPAR agonist, does not alter the pharmacokinetics of oral contraceptives (OC). Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
42. 42. Freed MI, Miller A, Jorkasky DK, et al. Rosiglitazone pharmacokinetics are not affected by coadministration of ranitidine [abstract]. Diabetes 1998 May; 47 Suppl. 1: A353
43. 43. DiCicco R. Allen A, Jorkasky D, et al. Lack of pharmacokinetic drug interaction between rosiglitazone (BRL 49653C) and metformin [abstract]. Clin Pharmacol Ther 1998 Feb; 63: 155
44. 44. Dicicco RA, Allen A. Jorkasky DK, et al. Chronic administration of rosiglitazone does not alter the pharmacokinetics of digoxin [abstract]. Diabetes 1998 May; 47 Suppl. 1: A353
45. 45. Inglis AML, Miller AK, Thompson KA, et al. Coadministration of rosiglitazone and acarbose (A): lack of a clinically relevant pharmacokinetic drag interaction [abstract]. Diabetes 1998 May; 47 Suppl. 1: A353
46. 46. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycemic control in patients with type 2 diabetes: a 12-week, ramdomized, placebo-controlled study. Diabetes Obesity Metab. In press
47. 47. Nolan JJ, Jones NP, Patwardhan R, et al. Once-daily rosiglitazone is effective in the treatment of type 2 diabetes mellitus. Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
48. 48. Grunberger G, Weston WM, Patwardhan R, et al. Rosíglitazone once or twice daily improves glycemic control in patients with type 2 diabetes. Poster accepted for American Diabetic Association Meeting; 1999 Jun 19-22, San Diego
49. 49. Patel J, Miller E, Patwardhan R. Rosiglitazone improves glycaemic control when used as a monotherapy in type 2 diabetic patients [abstract]. Diabetic Med 1998; 15 Suppl. 2: S37-8
50. 50. Raskin P, Rappaport EB. Rosiglitazone (RSG) improves fasting and postprandial plasma glucose in type 2 diabetes. Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
51. 51. Beebe KL, Patel J. Rosiglitazone is effective and well tolerated in patients ≥65 years with type 2 diabetes. Poster accepted for American Diabetic Association Meeting; 1999 Jun 19-22; San Diego
52. 52. Charbonnel B, Lönnqvist F, Jones NP, et al. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose alter 1 year of treatment in type 2 diabetes patients. Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
53. 53. Gomis R, Jones NP, Vallance SE, et al. Low-dose rosiglitazone (RSG) provides additional glycemic control when combined with sulfonylureas in type 2 diabetes (T2D). Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
54. 54. Fonseca V, Biswas N, Salzman A. Once-daily rosiglitazone (RSG) in combination with metformin (MET) effectively reduces hyperglycemia in patients with type 2 diabetes. Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
55. 55. Ruskin P, Dole JF, Rappaport EB. Rosiglitazone improves glycemic control in poorly controlled, insulin-treated type 2 diabetes. Poster accepted for American Diabetes Association Meeting 1999, Jun 19-22, San Diego
56. 56. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9
57. 57. Patel J, Weston WM, Hemyari P. Rosiglitazone (RSG) decreases insulin resistance (IR) and improves beta-cell function (BCF) in patients with type 2 diabetes mellitus (T2DM). SmithKline Beecham; data on file
58. 58. Data on file, SmithKline Beecham.
59. 59. Kreider M, Miller E, Patel J. Rosiglitazone is safe and well tolerated as monotherapy or combination therapy in patients with type 2 diabetes mellitus. Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
60. 60. Culkin KT, Patterson SD, Jorkasky DK, et al. Rosiglitazone (RSG) does not increase the risk of alcohol-induced hypoglycemia in diet-treated type 2 diabetics. Abstract accepted for American Diabetic Association Meeting; 1999 Jun 19-22, San Diego
61. 61. Salzman A, Patel J. Rosiglitazone is not associated with hepatotoxicity. Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
62. 62. Elcock FJ, Lyon JJ, Hitchcock J, et al. Toxicity of troglitazone in cultured rat hepatocytes. Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
63. 63. Dogterom P, Jonkman JHG, Vallance SE. Rosiglitazone; no effect on erythropoiesis or premature red cell destruction. SmithKline Beecham; data on file
64. 64. St John Sutton M, Dole J, Rappaport EB. Rosiglitazone does not adversely affect cardiac structure or function in patients with type 2 diabetes. Poster accepted for American Diabetes Association Meeting; 1999 Jun 19-22, San Diego
65. 65. Miller E, Patel J, Reichek N, et al. BRL 49653 (a thiazolidinedione) is well tolerated and has no effect on LV mass following 12 weeks treatment in NIDDM patients [abstract]. Diabetes 1997 May; 46 Suppl. 1: 96A
66. 66. Walker AB, Naderali EK, Chattington PD, et al. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998 May; 47: 810-4